- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01499407
Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction (COCTAIL II)
January 2, 2012 updated by: Francesco Prati, CLI Foundation
A Randomized Trial to Compare Four Different Intracoronary Modalities to Reduce Thrombus Burden and Improve Microcirculatory Function in Patients With ST-elevation Myocardial Infarction: Rationale and Design of the COCTAIL II Study
Subjects with ST-elevation myocardial infarction will be randomized, to one of the following: abciximab infusion with the ClearWay coronary catheter (C), standard abciximab infusion (A), thrombectomy followed by abciximab infusion with the ClearWay catheter (T+C), or thrombectomy followed by standard abciximab infusion (T+A).
The primary objective is to demonstrate that abciximab infusion with the ClearWay catheter with or without manual thrombus aspiration (groups C or T+C) will result in a significant reduction of intra-stent thrombus formations when compared to intravenous or intracoronary abciximab with or without thrombectomy (groups A or T+A).
The primary endpoint will be the number of cross sections with thrombus area >10% immediately after stent implantation as assessed with OCT.
Additional angiographic, ECG, and clinical endpoints will be collected and adjudicated.
This trial is currently being registered at ClinicalTrials.gov.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
128
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Francesco Prati, MD
- Email: fprati@hsangiovanni.roma.it
Study Locations
-
-
RM
-
Rome, RM, Italy, 00184
- Recruiting
- A. O. S. Giovanni Addolorata
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ischemic symptoms must be present at rest and last for at least 10 minutes,
- within 6 hours from onset of chest pain,
- ECG changes will be persistent ST-segment elevation or new-onset left bundle branch block,
- cardiac markers can be either in the normal range or elevated (troponin I or T and/or creatine kinase-myocardial band upper limit of normal for the local laboratory assay),
- coronary angiogram must be obtained within 6 hours from onset of symptom,
- the culprit artery must be identified in a native vessel and must show a significant lesion indicative of local thrombosis with TIMI flow 0-2
- patients must have signed the informed consent form prior to performance of trial-related procedures.
Exclusion Criteria:
- baseline TIMI flow 3,
- tortuosity of coronary vessels that may prevent negotiation of target lesions with the devices that are required by the protocol,
- myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease (e.g. arrhythmia, severe anemia, hypoxia, thyrotoxicosis, cocaine, severe valvular disease or hypotension),
- use of a fibrinolytic agent within 14 days prior to randomization,
- use of abciximab or any other glycoprotein IIb/IIIa inhibitor within 30 days prior to randomization,
- suspected active internal bleeding or history of hemorrhahagic diathesis,
- major surgery, biopsy of a parenchymal organ, eye surgery, or serious trauma within 6 weeks prior to randomization,
- gastrointestinal or genitourinary bleeding of clinical significance within 6 weeks prior to randomization,
- history of cerebrovascular accident (CVA) or transient ischemic attack within the previous 2 years or any CVA with a residual neurological deficit,
- administration of oral anticoagulants within 7 days prior to randomization unless prothrombin time ≤1.2 times control (or international normalized ratio ≤1.4),
- ongoing treatment with oral anticoagulant,
- known current platelet count less than 100.000 cells/µL,
- prior known intracranial neoplasm, arteriovenous malformation, aneurysm, or aneurysm repair,
- known allergy to abciximab or other murine proteins,
- known impaired renal function (estimated glomerular filtration rate <60 mL/min),
- coexistent condition associated with a limited life expectancy (e.g. advanced cancer),
- participation in any phase of another clinical research trial involving the evaluation of another investigational drug or device within 30 days prior to randomization, known positive pregnancy test for women of childbearing age.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard abciximab bolus
|
|
Experimental: ClearWay-infused abciximab
|
|
Experimental: Thrombectomy plus ClearWay-infused abciximab
|
|
Active Comparator: Thrombectomy plus standard abciximab bolus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thrombus area
Time Frame: 1 week
|
The primary endpoint of this trial will be the post-procedural number of cross sections with thrombus area >10% at optical coherence tomography.
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Anticipated)
December 1, 2012
Study Completion (Anticipated)
April 1, 2013
Study Registration Dates
First Submitted
December 21, 2011
First Submitted That Met QC Criteria
December 22, 2011
First Posted (Estimate)
December 26, 2011
Study Record Updates
Last Update Posted (Estimate)
January 5, 2012
Last Update Submitted That Met QC Criteria
January 2, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COCTAIL II
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ST-elevation Myocardial Infarction
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Inha University HospitalCompletedST Segment Elevation Myocardial Infarction | Non-ST Segment Elevation Myocardial InfarctionKorea, Republic of
-
RenJi HospitalCompletedST Segment Elevation Myocardial Infarction
-
Dong-A UniversityTerminatedST-Segment Elevation Myocardial InfarctionKorea, Republic of
-
Azienda Ospedaliera San Camillo ForlaniniUnknownST Segment Elevation Myocardial InfarctionItaly
-
Jinan Central HospitalUnknownST-Segment Elevation Myocardial InfarctionChina
Clinical Trials on Abciximab
-
Centocor, Inc.Eli Lilly and CompanyCompletedMyocardial InfarctionUnited States, France, United Kingdom, Belgium, Germany, Spain, Poland, Bulgaria, Romania, Israel, Sweden, Canada, Czech Republic, Argentina, Austria, Denmark, Netherlands, South Africa, Switzerland
-
University of LeipzigCompleted
-
University of LeipzigCompletedST-elevation Myocardial InfarctionGermany
-
Laval UniversityEli Lilly and Company; Cordis Corporation; Quebec Heart InstituteCompletedMyocardial Infarction | IschemiaCanada
-
Olivier F. BertrandEli Lilly and Company; Cordis CorporationCompletedMyocardial Infarction | IschemiaCanada
-
University of PisaEli Lilly and CompanyCompletedMyocardial InfarctionItaly
-
Università degli Studi di FerraraCompletedAcute Coronary SyndromeItaly
-
Azienda Sanitaria OspedalieraCardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, ItalyTerminatedMyocardial Infarction | Coronary DiseaseItaly
-
Aarhus University Hospital SkejbyDanish Heart FoundationCompletedPrimary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 HoursAcute Myocardial InfarctionDenmark
-
University Hospital TuebingenUnknownPatients Above 18 YearsGermany